Contact information
Rong Li
PhD
Career Development Fellow
I am a Career Development Fellow funded by Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS) based in MRC Weatherall Institute of Molecular Medicine (WIMM).
From 2018 to 2021, I was a Bloodwise-funded Postdoctoral Researcher working with Adam Mead and Bethan Psaila in WIMM. Prior to this, I was working towards my PhD from 2013-2018 in Peking Union Medical College in China. My DPhil research was mainly focused on the role of mesenchymal stem cells (MSC) in the progression of MPN. I developed extensive experience in MSC and haematopoietic stem cell assays, as well as MPN mouse models.
During my postdoctoral research, my research has focused on characterizing the role of megakaryocytes and how their interaction with stromal cells underlies the progression of myelofibrosis via single cell multi-omics techniques including 10x single cell sequencing, TARGET-seq and single cell ATAC-seq.
Recent publications
-
The BET inhibitor CPI203 promotes ex vivo expansion of cord blood long-term repopulating HSCs and megakaryocytes.
Journal article
Hua P. et al, (2020), Blood, 136, 2410 - 2415
-
Single-Cell Analyses Reveal Megakaryocyte-Biased Hematopoiesis in Myelofibrosis and Identify Mutant Clone-Specific Targets.
Journal article
Psaila B. et al, (2020), Mol Cell, 78, 477 - 492.e8
-
Loss of ASXL1 in the bone marrow niche dysregulates hematopoietic stem and progenitor cell fates
Journal article
Zhang P. et al, (2018), Cell Discovery, 4
-
TET2 Loss Dysregulates the Behavior of Mesenchymal Stem Cells and Increases Their Ability to Promote TET2−/−-Driven Myeloid Malignancy Progression
Journal article
Zhao Z., (2018), Journal of Global Oncology, 4, 222s - 222s
-
Reduced BAP1 activity prevents ASXL1 truncation-driven myeloid malignancy in vivo
Journal article
Guo Y. et al, (2018), Leukemia, 32, 1834 - 1837
-
Alteration in the Cytokine Secretion of Bone Marrow Stromal Cells from Patients with Chronic Myelomonocytic Leukemia Contribute to Impaired Hematopoietic Supportive Activity.
Journal article
Shi H. et al, (2018), Stem Cells Int, 2018
-
TET2 Loss Dysregulates the Behavior of Bone Marrow Mesenchymal Stromal Cells and Accelerates Tet2-Driven Myeloid Malignancy Progression
Journal article
Li R. et al, (2018), Stem Cell Reports, 10, 166 - 179